Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (6)
Type
(
1 selected
)
Type
Guidance (293)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (10)
Health technology evaluations (9)
Highly specialised technologies guidance (8)
Interventional procedures guidance (15)
Medical technologies guidance (13)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (293)
Apply filters
Showing 21 to 30 of 293
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Atogepant for preventing migraine [ID5090]
Technology appraisal guidance
15 May 2024
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
Technology appraisal guidance
TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Technology appraisal guidance
TBC
Avapritinib for treating advanced systemic mastocytosis ID3770
Technology appraisal guidance
TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Technology appraisal guidance
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Technology appraisal guidance
TBC
Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]
Technology appraisal guidance
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Technology appraisal guidance
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Technology appraisal guidance
TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212
Technology appraisal guidance
TBC
Previous page
1
2
Current page
3
4
5
…
30
Page
3
of
30
Next page
Results per page
10
25
50
All
Back to top